Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.
Why Invest in Myriad Genetics
Myriad's 9 molecular diagnostic tests provide a preeminent market position today; our 13 innovative pipeline tests will ensure Myriad's standing for the future. The Company is focused on three initiatives for long-term growth:
- To grow existing tests and markets;
- To expand internationally; and
- To launch new products including companion diagnostics.
While Myriad is investing in its future, the company also boasts a balanced capital approach including returning cash to shareholders.
Events & Presentations
Stock Quote (NASDAQ:MYGN)
Provided by eSignal.
Corporate Communications and Media Relations